TY - JOUR
T1 - Elimination of Cervical Cancer
T2 - Challenges Promoting the HPV Vaccine in China
AU - Wei, Lihui
AU - Xie, Xing
AU - Liu, Jihong
AU - Qiao, Youlin
AU - Zhao, Fanghui
AU - Wu, Ting
AU - Zhang, Jun
AU - Ma, Ding
AU - Kong, Beihua
AU - Chen, Wen
AU - Zhao, Chao
AU - Zhao, Yun
AU - Li, Jingran
AU - Li, Mingzhu
AU - Xia, Ningshao
N1 - Publisher Copyright:
© 2021, Association of Gynecologic Oncologists of India.
PY - 2021/9
Y1 - 2021/9
N2 - Objective: Cervical cancers present major threats to women’s health in China. Eliminating cervical cancer in China is a huge challenge, with application of the HPV vaccine, which is an important part. Methods: There are currently four HPV vaccines available in China: E-coli bv-HPV (Wantai, China), bv-HPV, qv-HPV (GSK, UK), and 9v-HPV (MSD, USA). To observe the immunogenicity, efficacy, and safety of these four vaccines in China, we formed the "Chinese Expert Consensus on the Clinical Application of HPV Vaccine." Results: At 7 months after vaccination, all vaccinated subjects had the same immunogenic response to either HPV16 or HPV18, ranging from 96 to 100%, and antibody production in girls aged 9–14 years was 2–3 times higher than that in adult women. Efficacy of the four vaccines against CIN2 + ranged from 87.3% to 100%, with prevention of HPV-associated infection reaching 96% ~ 97% at 12 months. Clinical trials showed bv-HPV and qv-HPV vaccine were also safe in women aged 18–45 years. Clinical trials of the 9v-HPV vaccine are underway. HPV vaccination is currently voluntary and self-paid in China. The "Chinese Expert Consensus on the Clinical Application of HPV Vaccine" will work to promote the application of HPV vaccine in China. Conclusions: In clinical studies, the available HPV vaccines showed excellent efficacy, safety, and immunogenicity in Chinese women. We will continue strengthening screening and encouraging HPV vaccination.
AB - Objective: Cervical cancers present major threats to women’s health in China. Eliminating cervical cancer in China is a huge challenge, with application of the HPV vaccine, which is an important part. Methods: There are currently four HPV vaccines available in China: E-coli bv-HPV (Wantai, China), bv-HPV, qv-HPV (GSK, UK), and 9v-HPV (MSD, USA). To observe the immunogenicity, efficacy, and safety of these four vaccines in China, we formed the "Chinese Expert Consensus on the Clinical Application of HPV Vaccine." Results: At 7 months after vaccination, all vaccinated subjects had the same immunogenic response to either HPV16 or HPV18, ranging from 96 to 100%, and antibody production in girls aged 9–14 years was 2–3 times higher than that in adult women. Efficacy of the four vaccines against CIN2 + ranged from 87.3% to 100%, with prevention of HPV-associated infection reaching 96% ~ 97% at 12 months. Clinical trials showed bv-HPV and qv-HPV vaccine were also safe in women aged 18–45 years. Clinical trials of the 9v-HPV vaccine are underway. HPV vaccination is currently voluntary and self-paid in China. The "Chinese Expert Consensus on the Clinical Application of HPV Vaccine" will work to promote the application of HPV vaccine in China. Conclusions: In clinical studies, the available HPV vaccines showed excellent efficacy, safety, and immunogenicity in Chinese women. We will continue strengthening screening and encouraging HPV vaccination.
KW - Efficacy
KW - Expert consensus
KW - HPV vaccine
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85114119885&partnerID=8YFLogxK
U2 - 10.1007/s40944-021-00536-6
DO - 10.1007/s40944-021-00536-6
M3 - Review article
AN - SCOPUS:85114119885
SN - 2363-8397
VL - 19
JO - Indian Journal of Gynecologic Oncology
JF - Indian Journal of Gynecologic Oncology
IS - 3
M1 - 51
ER -